Alisertib in Chemotherapy-pretreated Urothelial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 28, 2014

Primary Completion Date

July 2, 2015

Study Completion Date

October 12, 2016

Conditions
Bladder CancerTransitional Cell Carcinoma
Interventions
DRUG

Alisertib

"SINGLE-ARM, SINGLE-DRUG PHASE: Alisertib will be given PO in a dosage of 50 mg BID for 7 Days (Days 1-7) of each 21 day treatment cycle.~In the randomized phase, Experimental arm will consist of the following drugs:~Alisertib will be given PO in a dosage of 40 mg twice daily on days 1-3, 8-10 and 15-17 of a 28 day cycle.~Paclitaxel: 60 mg/m2 over 60 minutes on Days 1, 8, and 15 in a 28-day cycle."

DRUG

Paclitaxel

Placebo will be given PO. Paclitaxel will be infused at the dose of 80 mg/m2 IV over a period of 60 minutes on Days 1, 8, and 15 in a 28-day cycle.

DRUG

Placebo

Placebo oral tablets

Trial Locations (1)

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

All Listed Sponsors
lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER

NCT02109328 - Alisertib in Chemotherapy-pretreated Urothelial Cancer | Biotech Hunter | Biotech Hunter